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ScienceDirectThe phosphatidylinositol-3 kinase (PI3K) pathway is one of the
most frequently activated pathogenic signalling routes in
human cancers, making it a rational and important target for
innovative anticancer drug development and precision
medicine. The three main classes of PI3K inhibitors currently in
clinical testing comprise dual pan-Class I PI3K/mTOR inhibitors,
pan-Class I PI3K inhibitors lacking significant mTOR activity and
isoform-selective PI3K inhibitors. A major step forward in recent
years is the progression of over 30 small molecule PI3K inhibitors
into clinical trials and the first regulatory approval of the PI3Kd
inhibitor idelalisib for multiple B-cell malignancies. This review
article focuses on the progress made in the discovery and
development of novel PI3K inhibitors, with an emphasis on
antitumour activity and tolerability profiles for agents that have
entered clinical trials. We also discuss the key issues of drug
resistance, patient selection approaches and rational targeted
combinations. Finally, we envision the future development and
use of PI3K inhibitors for the treatment of patients with a range of
malignancies.
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Introduction
The phosphatidylinositol-3 kinase (PI3K) pathway is one
of the most frequently activated pathogenic signalling
routes in human cancers, affecting 30–50% of malignan-
cies, making it a rational and important target for innova-
tive anticancer drug development and precision medicine
[1,2]. There are four well-described Class I PI3K isoformsCurrent Opinion in Pharmacology 2015, 23:98–107 (a, b, d and g encoded by PIK3CA, PIK3CB, PIK3CD and
PIK3CG respectively) which catalyze phosphorylation of
phosphoinositides on the 30 position of the inositol ring,
and most importantly, the conversion of PtdIns(4,5) to
the second messenger PtdIns(3,4,5) or PIP3 — which in
turn recruits cytosolic proteins with PIP3-binding pleck-
strin homology (PH) domains (such as the serine/threo-
nine kinase protein kinase B/AKT), thereby localizing
them to the plasma membrane. The Class IA isoforms
(a, b and d) in particular are associated with oncogene-
sis, cancer progression and multiple hallmarks of malig-
nancy [3].
The PIK3CA gene, which encodes the p110a catalytic
subunit of PI3K, is the most commonly mutated kinase in
the human genome [4]. The identification of driver
PIK3CA mutations through tumour genome sequencing
provided the first example of a mutated lipid kinase
oncogene [5]. There is also evidence of PIK3CA am-
plification and overexpression in different cancers, as
well as numerous other oncogenic abnormalities, includ-
ing frequent mutation, deletion and loss of expression of
the tumour suppressor gene PTEN (Figure 1) [6,7].
Further research is required to delineate the relationship
of such aberrations with other oncogenic abnormalities,
so as to improve our understanding of potential mecha-
nisms of drug resistance, which may have implications
for the development of effective targeted combination
regimens.
A major step forward in recent years has been the pro-
gression of over 30 small molecule PI3K inhibitors into
clinical trials and the first regulatory approval of one such
agent, idelalisib (Zydelig, CAL-101; Gilead Sciences)
(see Figure 2 for representative chemical structures)
[8,9,10]. This present article focuses on the recent
progress made in the discovery and development of novel
PI3K inhibitors, with an emphasis on antitumour activity
and tolerability profiles for agents that have entered
clinical trials. We also discuss the key issues of patient
selection, drug resistance and rational targeted combina-
tions. Finally, we envision the future development and
use of PI3K inhibitors for the treatment of patients with a
range of different malignancies.
Current status of PI3K inhibitors
The three main classes of PI3K inhibitors currently in
clinical testing comprise dual pan-Class I PI3K/mTOR
inhibitors, pan-Class I PI3K inhibitors lacking significantwww.sciencedirect.com
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The PI3K pathway with respective PI3K inhibitors. When PI3K is activated, phosphatidylinositol 3,4,5-trisphosphate (PIP3) is generated from
phosphatidylinositol 3,4-bisphosphate (PIP2), and recruits AKT to the cell membrane [80,81]. This leads to a conformational change and
phosphorylation of AKT and its subsequent activation. AKT then translocates to the cytoplasm and nucleus, where phosphorylation of various
downstream substrates involved in the regulation of multiple cellular functions, including proliferation, survival and growth occurs. The PI3K
pathway is one of the most frequently activated signalling pathways in human cancers, affecting 30–50% of tumours, making it a rational target
for novel anticancer drug development. The red arrows indicate the respective mechanisms of action of different PI3K inhibitors, which include the
dual PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors and isoform-selective PI3K inhibitors. Individual examples of different PI3K inhibitors in
clinical testing are shown in the figure. The table in the figure lists the regulatory and catalytic subunits of the respective PI3K classes.mTOR activity and isoform-selective PI3K inhibitors [11].
The vast majority of these drugs are ATP-competitive
reversible kinase inhibitors, while PX-866 (Oncothyreon),
which is based on the earlier potent natural product but
unstable inhibitor wortmannin, is the only irreversible
PI3K inhibitor currently in clinical trial testing [12]. An
interesting spectrum of varying drug characteristics, with
respect to both antitumour activity and tolerability, has
been observed across the different PI3K inhibitors. Such
findings have influenced drug discovery and development
strategies and also regulatory registration approaches with
PI3K inhibitors.www.sciencedirect.com Of special note, in July 2014 the US Food and Drug
Administration (FDA) approved the first PI3K to be
licensed, namely the PI3Kd inhibitor idelalisib for dif-
ferent B-cell malignancies: as monotherapy for patients
with relapsed follicular B-cell non-Hodgkin lymphoma
and small lymphocytic lymphoma, and in combination
with rituximab for those with relapsed chronic lympho-
cytic leukemia (CLL) [8,9,10]. The other classes of
PI3K inhibitors are still in early to late clinical trial
testing in solid tumours and/or haematological malig-
nancies utilising either monotherapy or combination
strategies.Current Opinion in Pharmacology 2015, 23:98–107
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Chemical structures of PI3K inhibitors highlighted in this article.Tolerabilty profiles of PI3K inhibitors
The safety profiles of all three classes of PI3K inhibitors
are now well characterised through the clinical testing
of multiple agents. PI3K/mTOR inhibitors include
GDC-0980 (Genentech), which is related to the increas-
ingly used chemical tool compound PI-103 [13], PF-
04691502 (Pfizer), BEZ235 (Novartis), XL765 (Exelixis/
Sanofi-Aventis) and GSK2126458 (GlaxoSmithKline)
[11,14,15]. These agents share common, dose-depen-
dent drug-related toxicities comprising rash, fatigue,
hyperglycemia, as well as gastrointestinal symptoms
including nausea, vomiting and diarrhoea. Such effects
appear to be on-target, but differences in both frequency
and severity of certain adverse events between various
agents have been observed. Overall, these side-effectsCurrent Opinion in Pharmacology 2015, 23:98–107 have limited the long-term tolerability of the dual
PI3K/mTOR targeting agents.
Inhibitors that target essentially all the Class I PI3 kinases
with minimal or no mTOR inhibition include the oral
compounds pictilisib (GDC-0941; Genentech), buparlisib
(BKM120; Novartis), XL147 (SAR245408; Exelixis/
Sanofi) and PX-866, together with the intravenous
BAY80-6946 (copanlisib; Bayer) [16–20]. The toxicities
seen with this class of agents are similar, albeit probably
less severe to those observed with PI3K/mTOR inhibi-
tors, and include rash, hyperglycaemia, gastrointestinal
symptoms and fatigue. For the intravenous inhibitor
BAY80-6946, at its maximum tolerated dose, six of seven
evaluable patients required insulin treatment for glucosewww.sciencedirect.com
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dosing [21].
Despite the selectivity of the a, d and g isoform-specific
PI3K inhibitors, drug-related toxicities observed are gen-
erally similar to those observed with pan-Class I PI3K
inhibitors, including nausea, vomiting, diarrhoea and
fatigue. However, hyperglycaemia is frequently observed
with PI3Ka inhibitors such as BYL719 and GDC-0032
[22,23], in contrast to d and g isoform-specific PI3K
inhibitors for which myelosuppression with neutropenia
and raised liver transaminases have been reported, where-
as hyperglycaemia is relatively uncommon [8,9,10].
The disparate effects are consistent with the known
biology of PI3K isoforms [11]. However, there is a need
to develop better animal models to predict human toxi-
cities with PI3K inhibitors, and in particular to under-
stand any additive versus synergistic toxicities with
combination strategies involving these agents.
Antitumour activity of PI3K inhibitors
PI3K/mTOR inhibitors
With PI3K/mTOR inhibitors, despite the vertical block-
ade of the two different crucial nodes along the PI3K
signalling pathway, single agent antitumour activity has
been modest [11]. For example, only two of 78 patients,
one each with bladder and renal cell carcinoma, had
RECIST partial responses with GSK2126458 [24]. This
may partly be due to the narrow therapeutic window
associated with these drugs that limits their dose escala-
tion, or to the unselected populations of patients enrolled
into these early phase studies. Several PI3K/mTOR
inhibitors are currently being tested in ongoing single
agent or combination Phase II studies.
Pan-Class I PI3K inhibitors
Similarly, despite a favourable pharmacokinetic–pharma-
codynamic (PK–PD) profile, including evidence of target
engagement by measuring downstream phosphoprotein
biomarkers, only modest evidence of single agent anti-
tumour activity has been observed with the oral pan-Class
I PI3K inhibitors [16,17]. Anecdotal examples of antitu-
mour responses to pictilisib include a patient with onco-
genic V600E BRAF-mutant melanoma and another with
platinum-refractory epithelial ovarian cancer exhibiting
both PTEN expression loss and PIK3CA amplification
[16]. Interestingly, in an expansion cohort of patients with
non-Hodgkin’s lymphoma treated with BAY80-6946,
5 RECIST partial responses were observed in six evalu-
able patients, with FDG-PET studies confirming disease
regression [21]. A phase II study of BAY80-6946 in
patients with non-Hodgkin’s lymphoma is ongoing
(NCT01660451) [25]. Activity in this setting is likely
to be driven by the subnanomolar IC50 potency of
BAY80-6946 against PI3Kd [26].www.sciencedirect.com Isoform-selective PI3K inhibitors
PI3Kd isoform-specific inhibitors
As discussed, robust single agent clinical activity has been
observed with the FDA-approved PI3Kd inhibitor idela-
lisib in B-cell malignancies that exhibit lineage-depen-
dency on this isoform. PI3Kd plays a crucial role in B cell
regulation, including proliferation and survival, and
demonstrates high expression in leukocytes [27]. The
observation that PI3Kd is especially hyperactivated in
different B cell cancers provided strong rationale for
developing potent and PI3Kd-isoform specific inhibitors
in such haematological malignancies, rather than solid
tumours [28]. This was supported by multiple preclinical
studies demonstrating that such a strategy would lead to
selective B cell cytotoxicity with minimal effects on other
haematopoietic cells [29].
It is likely that its increased increased specificity for the
PI3Kd isoform, together with reduced hyperglycaemia
has enabled the administration of relatively higher doses
of idelalisib, leading to enhanced target and pathway
suppression, potentially greater than that obtainable with
dual PI3K/mTOR inhibitors and pan-Class I PI3K inhi-
bitors. Another promising PI3Kd isoform-specific PI3K
inhibitor is IPI-145 (Infinity Pharmaceuticals) which has
also demonstrated impressive results in patients with
relapsed haematological cancers, including CLL and
lymphoma [30].
PI3Ka isoform-specific inhibitors
While there is a general lack of consensus between
studies involving PIK3CA mutant cell sensitivity to
pan-Class I PI3K inhibition [31–36], recent preclinical
studies indicate that PIK3CA mutant cancer cells are
indeed more sensitive to the p110a-specific inhibitors
BYL719 (Novartis) and INK1117 (Millennium) [37,38]
and the ‘p110b-sparing’ p110a inhibitors GDC-0032
(Genentech) and CH5132799 (Chugai Pharmaceutical)
[33,39]. Early phase clinical trials involving the p110a
inhibitors BYL719 and GDC-0032 have demonstrated
signals of therapeutic activity with RECIST responses
in PIK3CA mutant solid tumours, providing early proof-
of-concept for this targeted monotherapy approach
[22,23].
On the basis of a robust preclinical relationship, only
patients with advanced solid tumours harbouring PIK3CA
aberrations were enrolled onto the phase I trial of p110a-
specific BYL719; of 102 patients treated, nine RECIST
partial responses (four confirmed) were reported [22].
Similarly, in the first-in-human phase I study of GDC-
0032, from 12 patients with PIK3CA mutant solid
tumours, five objective responses were reported [23].
Four of these PIK3CA mutant responders had breast
cancer, indicating a potential molecularly selected
tumour type for more focused clinical testing in the
future. This is especially important since only one furtherCurrent Opinion in Pharmacology 2015, 23:98–107
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different advanced solid cancers, which were all con-
firmed to be PIK3CA wildtype.
PI3Kb isoform-specific inhibitors
Preclinical data have indicated that PI3Kb isoform-spe-
cific inhibition is more potently effective in cancer cells
with PTEN loss [40,41], and clinical trials involving
PI3Kb-targeted inhibitors GSK-2636771 (GlaxoSmithK-
line) [42] and AZD8186 (AstraZeneca) [43] are currently
ongoing to explore the safety and antitumour activity in
patients with tumours characterised by PTEN deficiency
or PI3Kb aberrations. Interestingly, the phase I trial of
GSK2636771 demonstrated PI3K pathway inhibition, but
limited antitumour activity in patients with PTEN-defi-
cient tumours [42]. However, early signals of antitumour
activity with RECIST responses were observed, suggest-
ing that patients with tumours harbouring concomitant
genetic alterations in PIK3CB may benefit from PI3Kb
blockade; exploratory genomic analyses of tumour sam-
ples from 10 prostate cancer patients revealed a PIK3CB
L1049R mutation in a tumour specimen from a patient
who remained on study for 33 weeks, and an increased
tumoural PIK3CB gene copy number in a patient who
achieved a RECIST partial response.
Recently, important insights have been revealed about
potential limitations of a and b isoform-specific PI3K
inhibitors. With regards to PTEN loss and p110b depen-
dency, evidence now suggests that concurrent mutations
that activate p110a, such as an activated KRAS mutation,
can cause a context-dependent shift away from PI3Kb
inhibitor sensitivity to PI3Ka inhibitor responsiveness
[44]. Furthermore, recent studies demonstrate that cancer
cells which are initially dependent upon either PI3Ka or
PI3Kb can overcome isoform-specific inhibitory selection
pressures through the upregulation of the alternate class I
isoform [45,46]. Crucially, these recent data demon-
strate a level of robustness in PI3K signalling, suggesting
that pan-Class I PI3K inhibitors or the combination of
potent PI3Ka and PI3Kb inhibitors may ultimately be
required to impact different cancers by suppressing or
overcoming the upregulation of the non-targeted PI3K
isoforms.
Challenges in patient selection strategies
Moving forward, it will be important to establish clear
patient selection criteria using predictive biomarkers of
response and resistance for the different classes of PI3K
inhibitors. Such patient selection is however complex
and multi-factorial, and is likely to be affected by issues
of intra-tumoural and inter-tumoural heterogeneity [47]
and also by the development of crosstalk and disruption
of signalling feedback loops [48]. For example, a recent
study demonstrated that the frequent presence of sub-
clonal driver mutations, such as E545K PIK3CA, may
necessitate the stratification of targeted therapy responseCurrent Opinion in Pharmacology 2015, 23:98–107 according to the percentage of tumour cells in which the
driver is identified [49]. Positioning of PI3K gene muta-
tions on the trunk or branches of evolutionary trees is also
likely to be important for the extent or duration of
response.
Genotype-based sensitivity correlation studies that in-
cluded PI3K inhibitors have involved the assessment of
large cancer cell line panels in high-profile publicly
available publications and associated datasets such as
the Cancer Genome Project (CGP, Sanger Centre) and
the Cancer Cell Line Encyclopaedia (CCLE, Broad
Institute) [50,51]. Overall, large discrepancies were iden-
tified between the sensitivity-genotype associations iden-
tified by these two data sources, although the DNA
sequencing and RNA expression data were found to be
concordant [52]. Because of this lack of consensus, it is
currently unclear which of these genetic associations are
fully robust and further studies are required to resolve
this. Note that it is important to consider precise PI3K
isoform selectivities and to include multiple different
inhibitor chemotypes so as to minimize off-target effects
and maximize robustness of findings [53].
Animal models are important to establish the quantitative
extent and duration of on-target and pathway inhibition
necessary for both biological and therapeutic effects [54].
These data can then be used to correlate preclinical PK–
PD profiles to toxicity and efficacy results. For example,
preclinical studies of the pan-Class I PI3K inhibitor
pictilisib demonstrated that greater than 90% inhibition
of AKT phosphorylation over several hours is required for
50% reduction in the number of proliferating cancer cells
in vitro and subsequent growth arrest in tumour xeno-
grafts [20,55]. In the subsequent phase I trial of pictilisib,
PK was dose-proportional, while phosphorylated AKT
levels were suppressed >90% in both platelet-rich plasma
at 3 h after dosing and in tumour at doses associated with
PK (area under curve [AUC]) >20 h mmol/L [16]. Signifi-
cant increases in plasma insulin and glucose levels, as well
as >25% decrease in (18)F-fludeoxyglucose (FDG) up-
take by positron emission tomography (PET) in seven of
32 evaluable patients also confirmed target modulation.
Despite these promising PK–PD data, single agent anti-
tumour activity was modest, with limited RECIST
responses observed [16].
Drug response prediction studies have generally utilised
mutation, copy number and gene fusion data to generate a
measure of pathway deregulation. This strategy has
allowed accurate prospective identification of cancer cells
sensitive to the pan-Class I PI3K agent pictilisib (false-
discovery rate or FDR < 1010) and the dual class I PI3K/
mTOR drug GDC-0980 (FDR < 0.0019), as well as other
targeted agents in a large panel of cancer cell lines [56]. In
the future, it will be crucial to test the predictive power of
such an aggregate scoring system of signalling pathwaywww.sciencedirect.com
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teomic data and using patient-derived samples and clini-
cally defined response criteria to assess if this approach
can reliably identify patients who are likely to respond to
PI3K inhibitors.
Rational targeted combination strategies
With the exception of the d-targeted drugs, because of
modest clinical effects observed so far with single agent
PI3K inhibitors — certainly less than is seen with BRAF,
MEK, EGFR and ALK inhibitors in the corresponding
vulnerable genotypes — it is important that rational com-
binations of PI3K inhibitors are pursued to maximize the
chances of revealing their full therapeutic potential in
cancer patients. Moreover, this is additionally important
because the PI3K pathway is a common mechanism of
resistance to multiple targeted agents, and conversely,
resistance to PI3K inhibitors may also develop due to
aberrant compensatory signalling through other path-
ways. Some currently pertinent combination strategies
are described in this section.
Activating PIK3CA mutations are the most frequent ge-
nomic alterations in oestrogen receptor (ER)-positive
breast cancers and PI3K inhibition results in increased
expression of ESR1 mRNA and ER protein together with
enhanced ER-driven transcriptional activity, with these
effects seen in laboratory models and in tumours from
patients treated with the PI3Ka-specific inhibitor
BYL719 [57]. Importantly, data from preclinical models
show that the anti-ER drug fulvestrant markedly
increases the response of ER-positive tumours to PI3Ka
inhibition, resulting in major tumour regression in in vivo
animal models, suggesting that combined PI3K and ER
inhibition is a rational approach to target such tumours.
Building on this, a randomized phase II breast cancer
study (FERGI) assessing the combination of pictilisib
and the ER antagonist fulvestrant in ER-positive aroma-
tase inhibitor-resistant advanced or metastatic breast can-
cer was recently reported [58]. In this study, although no
overall difference was observed in median progression-
free survival (PFS) between the combination of pictilisib
and fulvestrant versus placebo and fulvestrant, an explor-
atory analysis demonstrated that patients who were both
ER and progesterone receptor (PR) positive were 56%
less likely to have disease progression when treated with
the experimental arm versus placebo (median PFS,
7.4 versus 3.7 months; p = 0.002).
CDK4/6 inhibition was shown to sensitise cancer cells to
PI3K inhibition, producing a greater reduction of cell
viability. Tumours from patients responding to the PI3-
Ka-specific inhibitor BYL719 demonstrated suppression
of RB phosphorylation, while non-responding tumours
exhibited sustained or increased levels of phospho-
RB after treatment [59]. This suggested persistentwww.sciencedirect.com phosphorylated Rb post-PI3K inhibitor exposure as a
potential clinical marker of acquired or intrinsic resistance
to PI3K inhibition. Furthermore, the combination of
PI3K and CDK4/6 inhibitors was shown to overcome
intrinsic and adaptive PI3K inhibitor resistance, causing
regressions in PIK3CA mutant tumour xenograft models.
Clinical studies are underway with the combination of
CDK4/6 and PI3K inhibitors [60].
Resistance to PI3K inhibitors has been observed in cancer
cells in which upstream signalling is increased via upre-
gulated secretion of the EGFR ligand amphiregulin [61],
increased expression of receptor tyrosine kinases (RTKs)
such as EGFR, HER3 and IGF1R/IR due to FOXO-
mediated transcriptional upregulation [62], and activated
NOTCH signalling [63]. Promising preclinical data gen-
erated from studies combining RTK and PI3K inhibitors
indicate that antitumour responses to PI3K inhibition can
be significantly enhanced in triple negative breast cancer
models through the combination with a dual EGFR/
HER3 antagonist in vitro and in vivo, with important
implications for this relatively hard to treat subtype
[64]. Overexpression of kinases RSK3 and RSK4 has also
been demonstrated to confer resistance to PI3K inhibitors
through the attenuation of apoptosis and upregulation of
protein translation [65].
Other resistance mechanisms to PI3K inhibitors involving
MYC oncogene activation have also been proposed. A
chemical genetic screen in breast cancer cell lines impli-
cated the activation of both MYC and Notch pathways as
putative resistance mechanisms to PI3K inhibitors [63].
Use of an engineered mouse model with an activated
PIK3CA H1047R allele showed that MYC activation
resulted in acquired resistance to specific PI3K inhibitors,
independent of the PI3K pathway [66], while a study of
genetically defined mammary epithelial cells also impli-
cated either MYC or eukaryotic translation initiation
factor 4E (eIF4E) amplification, both associated with
elevated 50 cap-dependent protein translation, as a resis-
tance mechanism to the dual PI3K/mTOR inhibitor
BEZ235 [67]. This indicates that drivers of protein trans-
lation confer resistance to PI3K pathway-targeted drugs.
The preclinical combination of PI3Ka inhibitors with
EGFR, AXL, or PKC inhibitors can overcome the resis-
tance observed in squamous cell carcinomas (SCC) of the
head and neck, where SCC cells that become resistant to
PI3Ka inhibition maintain PI3K-independent activation
of mTOR [68].
The oncogenic RAS–RAF–MEK–ERK MAPK pathway
is possibly the most commonly reported escape mecha-
nism following PI3K pathway inhibition because of sig-
nalling crosstalk [35,69]. While dual inhibition of PI3K
and MAPK signalling has been reported to be synergistic
for increased cell death in preclinical models, data alsoCurrent Opinion in Pharmacology 2015, 23:98–107
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ping toxicities may be a challenge to the clinical success
of this combination, unless intermittent dosing strategies
prove efficacious [70]. For example, during the Phase I
study of the combination of the PI3K/mTOR inhibitor
SAR245409 (Merck Serono) and MEK inhibitor pimaser-
tib, escalation to their single agent doses was precluded
because of dose-limiting toxicities and the requirement
for dose modifications with chronic dosing [71]. A phase
Ib trial of buparlisib and the MEK1/2 inhibitor trametinib
(GSK) showed promising antitumour activity in patients
with KRAS mutant ovarian cancer; however, the chronic
tolerability of the combination at the recommended
phase II dose was challenging, due to frequent dose
interruptions and reductions for toxicity [72].
A recent preclinical study showed that baseline PI3K
activation is associated with greater resistance to inhibi-
tors of poly-ADP ribose polymerase (PARP) in small cell
lung cancer [73]. Previous studies had demonstrated
synergy between PARP and PI3K inhibitors in
BRCA1-deficient mouse models [74] and shown that
PI3K blockade promotes homologous recombination de-
ficiency by downregulating BRCA, thereby sensitising
BRCA-proficient tumours to PARP inhibition [75]. An-
other study supported the combinatorial inhibition of
PARP and PI3K as an effective option for PTEN-defi-
cient prostate cancer [76]. Clinical trials have recently
begun to test this rational combination hypothesis in
cancer patients [25].
Future perspectives and conclusion
Together with the approval of the PI3Kd inhibitor ide-
lalisib for different B-cell malignancies, there is now a
large armamentarium of different PI3K inhibitors with
diverse isoform-selectivity profiles in early to late clinical
trial testing, involving both monotherapy and combina-
tion strategies. Learning from the success with the PI3Kd
inhibitors and noting the modest clinical benefit to date
with single agent administration of other PI3K drug
classes, it is clear that we need to refine our views both
of target involvement and the corresponding therapeutic
strategies. Rational patient selection through the use of
analytically validated and clinically qualified predictive
biomarkers will be crucial. Obtaining tumour biopsies for
molecular profiling as well as minimally invasive analysis,
such as use of circulating plasma DNA, will be important
to predict sensitive and resistant patients, with further
refinement to identify clonal involvement to guide treat-
ment selection [77].
Of likely importance is a very recent report that — in
contrast to mutations in the RAS–MEK signalling axis
that were less subclonal — 15% of mutations in genes in
the PI3K–AKT–mTOR signalling axis across different
tumour types are subclonal rather than truncal [49].
Responses are likely to be less impressive and durableCurrent Opinion in Pharmacology 2015, 23:98–107 where oncogenic mutations are subclonal rather than
truncal.
Where single agent PI3K inhibitor activity is not likely to
be effective owing to factors such as the lack of appropriate
genomic aberrations, the presence of clonal heterogeneity
or the development of adaptive feedback loops, it will be
essential to combine PI3K inhibitors — either with other
molecularly targeted drugs, hormonal agents, or alterna-
tively cytotoxic chemotherapy — in order to fully reveal
their full therapeutic potential. Such advances will only be
possible through further improvements in our understand-
ing of the underlying biology of tumours and the develop-
ment of appropriate isoform-selective drugs in specific
molecular settings. It is likely that there will continue to
be unexpected surprises. For example, amplification of the
mutant PIK3CA locus has been demonstrated to produce
resistance to PI3K inhibition [78].
Thereafter, we will need to identify the best PI3K
inhibitor combinations and to prioritize for clinical evalu-
ation those with the highest likelihood of patient benefit
and minimal toxicity. In the future, as preclinical models
and molecular profiling technologies become increasingly
sophisticated and robust, it is likely that we will have the
necessary biomarker tools and knowledge to support
clinical combination trials. For example, patient-derived
models of acquired resistance have recently been shown
in promising early studies to enable identification of
effective drug combinations for use in patients with
non-small cell lung cancer [79]. Ultimately, combina-
tion studies involving PI3K inhibitors may be limited by
toxicity, and it will therefore be important to explore
different dosing regimens, including pulsatile schedules,
which may improve tolerability and optimise antitumour
activity. With such intermittent schedules, it may even be
possible to combine multiple drugs akin to approaches
used successfully to combat drug resistance in infections
such as HIV.
In conclusion, these are exciting times in precision cancer
medicine, with a range of different PI3K inhibitors avail-
able for use either as monotherapy or in combination
regimens. We now need to refine the clinical application
of PI3K inhibitors with different isoform selectivities
using robust predictive biomarkers and rational combina-
torial use with other antitumour agents, so as to maximally
impact cancer and provide patients with the greatest
chance of valuable benefit.
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